Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment

Introduction

Date

22 Sep 2020

Session

ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment

Presenters

Giuseppe Curigliano

Authors

G. Curigliano

Author affiliations

  • Early Drug Development for Innovative Therapies Division, IEO - Istituto Europeo di Oncologia, 20141 - Milan/IT
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings